PD-L1 prevalence in advanced urothelial carcinoma by demographic and clinical characteristics

被引：0

作者：

Powles, T. B. ^{[1
]}

van der Heijden, M. S. ^{[2
]}

Balar, A. V. ^{[3
]}

O'Donnell, P. ^{[4
]}

Massard, C. ^{[5
]}

Walker, J. ^{[6
]}

Gupta, A. ^{[7
]}

Angra, N. ^{[7
]}

Cairns, J. ^{[8
]}

Turriziani, B. ^{[6
]}

Rebelatto, M. C. ^{[7
]}

Scott, M. ^{[6
]}

Wildsmith, S. ^{[6
]}

机构：

[1] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England

[2] Netherlands Canc Inst, Div Med Oncol, Amsterdam, Netherlands

[3] NYU, Dept Med, Perlmutter Canc Ctr, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA

[4] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA

[5] Gustave Roussy Canc Campus, DITEP, Villejuif, France

[6] AstraZeneca, Oncol R&D, Cambridge, England

[7] AstraZeneca, Oncol R&D, Gaithersburg, MD USA

[8] AstraZeneca, Stat, Cambridge, England

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.10.498

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

13P

引用

页码：S1421 / S1421

页数：1

共 50 条

[21] PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis
Ghate, Ketan
Amir, Eitan
Kuksis, Markus
Hernandez-Barajas, David
Rodriguez-Romo, Laura
Booth, Christopher M.
Vera-Badillo, Francisco E.
CANCER TREATMENT REVIEWS, 2019, 76 : 51 - 56
[22] PREVALENCE OF PD-L1 AND OTHER SELECTED BIOMARKERS IN ADVANCED UROTHELIAL AND ESOPHAGEAL CARCINOMA AND ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA IN TWO REFERENCE INSTITUTIONS OF COLOMBIA
Hinestrosa, F.
Urrego-Reyes, J.
Beltran, C.
Gaitan Hemelberg, M. A.
Escobar, J.
Rodriguez, J.
Cardona, A. F.
VALUE IN HEALTH, 2022, 25 (12) : S482 - S482
[23] Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
Spassova, Ivelina
Ugurel, Selma
Kubat, Linda
Zimmer, Lisa
Terheyden, Patrick
Mohr, Annalena
Andtback, Hannah Bjorn
Villabona, Lisa
Leiter, Ulrike
Eigentler, Thomas
Loquai, Carmen
Hassel, Jessica C.
Gambichler, Thilo
Haferkamp, Sebastian
Mohr, Peter
Pfoehler, Claudia
Heinzerling, Lucie
Gutzmer, Ralf
Utikal, Jochen S.
Horny, Kai
Schildhaus, Hans-Ulrich
Habermann, Daniel
Hoffmann, Daniel
Schadendorf, Dirk
Becker, Juergen Christian
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
[24] PD-L1 Immunoreactivity and Immune Pathway Markers in Urothelial Carcinoma
McKnight, Tristan F.
Tacha, David
Shabaik, Ahmed
Hansel, Donna
LABORATORY INVESTIGATION, 2018, 98 : 367 - 367
[25] Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
Tosev, Georgi
Wahafu, Wasilijiang
Reimold, Philipp
Damgov, Ivan
Schwab, Constantin
Aksoy, Cem
Kaczorowski, Adam
Stenzinger, Albrecht
Nyarangi-Dix, Joanne
Hohenfellner, Markus
Duensing, Stefan
SCIENTIFIC REPORTS, 2021, 11 (01)
[26] A study of PD-L1 diagnostic assay concordance in urothelial carcinoma
Zajac, Magdalena
Scott, Marietta
Ratcliffe, Marianne
Sharpe, Alan
Scorer, Paul W.
Barker, Craig
Al-Masri, Hytham
Rebelatto, Marlon
Walker, Jill
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[27] PD-L1 and IDO Expression in Upper Tract Urothelial Carcinoma
Cathro, Helen
Ju, Jennifer
Davick, Jonathan
Gru, Alejandro A.
Culp, Stephen
MODERN PATHOLOGY, 2019, 32
[28] PD-L1 and IDO Expression in Upper Tract Urothelial Carcinoma
Cathro, Helen
Ju, Jennifer
Davick, Jonathan
Gru, Alejandro A.
Culp, Stephen
LABORATORY INVESTIGATION, 2019, 99
[29] PD-L1 Immunoreactivity and Immune Pathway Markers in Urothelial Carcinoma
McKnight, Tristan F.
Tacha, David
Shabaik, Ahmed
Hansel, Donna
MODERN PATHOLOGY, 2018, 31 : 367 - 367
[30] Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?
Sonpavde, Guru
Dranitsaris, George
Necchi, Andrea
EUROPEAN UROLOGY, 2018, 74 (01) : 63 - 65

← 1 2 3 4 5 →